| Supplementary Protection Certificate (SPC) Summary | |||||||||
| SPC No. | 2013/034 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of filing | 12/07/2013 | ||||||||
| Notification of Application Published | 14/08/2013 | ||||||||
| Status | Granted | ||||||||
| Notification of Grant Published | 29/07/2015 | ||||||||
| Date of Expiry of SPC | 22/07/2028 | ||||||||
| Applicant |
NOVO NORDISK A/S Novo Alle 2880 Bagsvaerd DENMARK |
||||||||
| Patent Number | 2107069 | ||||||||
| Title of Invention | Novel insulin derivatives | ||||||||
| Date of Expiry of Patent | 21/07/2024 | ||||||||
| Product Type | Medicinal Product | ||||||||
| Product Identity | Insulin degludec | Market Authorisation | Ireland | European Union | |||||
| Authorisation No | EU/1/12/807-001, 004, 005, 007-009, 012, 013 and 015 | EU/1/12/807-001, 004, 005, 007-009, 012, 013 and 015 | |||||||
| Authorisation Date | 21/01/2013 | 21/01/2013 | |||||||
| Identity of Product Authorised | Tresiba-insulin degludec | Tresiba-insulin degludec | |||||||
| Address for Service |
TOMKINS & CO. 5 Dartmouth Road Dublin 6 IRELAND |
||||||||
| Renewal Fees |
|
||||||||
| 17/11/2015 | The expiry date of SPC No. 2013/034 has been amended to bring it into line with the decision from the Court of Justice of the European Union in Case C-471/14. New expiry date is 22/01/2028. | ||||||||
| 12/01/2017 | Application for an extension of the duration of Supplementary Protection Certificate No. 2013/034 filed on 20/12/2016. | ||||||||
| 12/03/2018 | Application for an extension of the duration of Supplementary Protection Certificate No. 2013/034 granted on 12/03/2018. Expiry date of SPC changed from 22/01/2028 to 22/07/2028. | ||||||||